Halozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley Sells 10,000 Shares

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $70.21, for a total value of $702,100.00. Following the sale, the chief executive officer directly owned 767,780 shares in the company, valued at $53,905,833.80. The trade was a 1.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Helen Torley also recently made the following trade(s):

• On Monday, March 2nd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $69.69, for a total transaction of $1,393,800.00.
• On Thursday, February 5th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $78.64, for a total transaction of $786,400.00.
• On Tuesday, February 3rd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $76.12, for a total transaction of $1,522,400.00.

Halozyme Therapeutics Trading Up 0.9%

Shares of Halozyme Therapeutics stock traded up $0.62 during trading on Wednesday, hitting $70.02. The company’s stock had a trading volume of 1,684,507 shares, compared to its average volume of 2,042,782. The stock has a market cap of $8.26 billion, a price-to-earnings ratio of 28.12, a price-to-earnings-growth ratio of 0.28 and a beta of 0.98. The company has a debt-to-equity ratio of 43.89, a current ratio of 4.66 and a quick ratio of 3.66. Halozyme Therapeutics, Inc. has a 52 week low of $47.50 and a 52 week high of $82.22. The stock has a 50-day moving average price of $72.71 and a two-hundred day moving average price of $70.76.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of $1.92 by ($2.16). Halozyme Therapeutics had a net margin of 22.69% and a return on equity of 136.12%. The company had revenue of $451.77 million during the quarter, compared to the consensus estimate of $446.13 million. During the same quarter last year, the firm posted $1.26 EPS. The company’s quarterly revenue was up 51.6% on a year-over-year basis. Equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Benchmark upped their price target on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, February 19th. The Goldman Sachs Group reissued a “sell” rating and issued a $56.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, December 4th. Citizens Jmp raised their price objective on shares of Halozyme Therapeutics from $91.00 to $92.00 and gave the stock a “market outperform” rating in a research report on Tuesday, November 4th. Weiss Ratings downgraded shares of Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research report on Tuesday, February 24th. Finally, TD Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, February 18th. Six equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Halozyme Therapeutics has an average rating of “Hold” and an average price target of $78.56.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of HALO. Measured Wealth Private Client Group LLC boosted its holdings in Halozyme Therapeutics by 51.5% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 124 shares during the last quarter. Abel Hall LLC grew its position in Halozyme Therapeutics by 4.2% in the 4th quarter. Abel Hall LLC now owns 3,216 shares of the biopharmaceutical company’s stock worth $216,000 after purchasing an additional 129 shares in the last quarter. StoneX Group Inc. increased its stake in Halozyme Therapeutics by 3.8% in the 4th quarter. StoneX Group Inc. now owns 3,650 shares of the biopharmaceutical company’s stock valued at $246,000 after buying an additional 132 shares during the last quarter. Moran Wealth Management LLC lifted its position in shares of Halozyme Therapeutics by 0.4% during the 4th quarter. Moran Wealth Management LLC now owns 35,596 shares of the biopharmaceutical company’s stock worth $2,396,000 after buying an additional 151 shares in the last quarter. Finally, Campbell Newman Asset Management Inc. boosted its position in Halozyme Therapeutics by 0.4% in the third quarter. Campbell Newman Asset Management Inc. now owns 36,878 shares of the biopharmaceutical company’s stock worth $2,705,000 after purchasing an additional 153 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.